DOID:0050687

Name:	cell type cancer
Namespace:	disease_ontology
Definition:	"A cancer that is classified by the type of cell from which it is derived." [url:http\://cancerguide.org/basic.html, url:http\://en.wikipedia.org/wiki/Cancer]
Created by:	snadendla
Creation date:	2011-06-13T03:28:50Z

Ontology association<br>Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies.<br><br>link to ontology dataset<br>data

---

Parents

is_a:	DOID:162(cancer)

Children

is a:	DOID:1115 (sarcoma),DOID:154 (mixed cell type cancer),DOID:1909 (melanoma),DOID:2994 (germ cell cancer),DOID:305 (carcinoma),DOID:3070 (malignant glioma),DOID:3350 (mesenchymal cell neoplasm)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

• 10408-106B3 (lung adenocarcinoma cell line:PC-14)
• 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
• 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
• 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
• 10415-106C1 (gall bladder carcinoma cell line:TGBC2TKB)
• 10417-106C3 (papillotubular adenocarcinoma cell line:TGBC18TKB)
• 10418-106C4 (transitional-cell carcinoma cell line:5637)
• 10419-106C5 (breast carcinoma cell line:MDA-MB-453)
• 10420-106C6 (colon carcinoma cell line:COLO-320)
• 10423-106C9 (choriocarcinoma cell line:BeWo)

... further results Mouse (Mus musculus)

• 10408-106B3 (lung adenocarcinoma cell line:PC-14)
• 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
• 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
• 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
• 10415-106C1 (gall bladder carcinoma cell line:TGBC2TKB)
• 10417-106C3 (papillotubular adenocarcinoma cell line:TGBC18TKB)
• 10418-106C4 (transitional-cell carcinoma cell line:5637)
• 10419-106C5 (breast carcinoma cell line:MDA-MB-453)
• 10420-106C6 (colon carcinoma cell line:COLO-320)
• 10423-106C9 (choriocarcinoma cell line:BeWo)

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:0050687 (cell type cancer), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

---

Copy Excel CSV PDF

Show 102550100 entries

Search:

P-value	FFCP	Short description

P-value	FFCP	Short description
7.3e-52	FFCP PHASE1:Hg19::chr9:97317348..97317379,+	p1@uc004aus.1
7.3e-52	FFCP PHASE2:Hg19::chr9:97317348..97317379,+	p1@uc004aus.1
1.13e-48	FFCP PHASE2:Hg19::chr7:156803329..156803362,-	p1@MNX1
1.13e-48	FFCP PHASE1:Hg19::chr7:156803329..156803362,-	p1@MNX1
2.83e-48	FFCP PHASE1:Hg19::chrX:153991088..153991168,+	p1@DKC1
2.83e-48	FFCP PHASE2:Hg19::chrX:153991088..153991168,+	p1@DKC1
1.03e-46	FFCP PHASE1:Hg19::chr12:20975472..20975489,+	p@chr12:20975472..20975489, +
1.03e-46	FFCP PHASE2:Hg19::chr12:20975472..20975489,+	p@chr12:20975472..20975489, +
5.89e-46	FFCP PHASE1:Hg19::chr20:57617831..57617909,-	p1@SLMO2
5.89e-46	FFCP PHASE2:Hg19::chr20:57617831..57617909,-	p1@SLMO2
7.24e-46	FFCP PHASE2:Hg19::chr7:1595871..1595896,-	p5@TMEM184A
7.24e-46	FFCP PHASE1:Hg19::chr7:1595871..1595896,-	p5@TMEM184A
2.27e-45	FFCP PHASE1:Hg19::chr8:120221345..120221393,+	p3@MAL2
2.27e-45	FFCP PHASE2:Hg19::chr8:120221345..120221393,+	p3@MAL2
2.41e-45	FFCP PHASE2:Hg19::chr11:1372935..1372952,+	p@chr11:1372935..1372952, +
2.41e-45	FFCP PHASE1:Hg19::chr11:1372935..1372952,+	p@chr11:1372935..1372952, +
4.37e-45	FFCP PHASE2:Hg19::chr3:180707436..180707451,-	p2@DNAJC19
4.37e-45	FFCP PHASE1:Hg19::chr3:180707436..180707451,-	p2@DNAJC19
4.42e-45	FFCP PHASE2:Hg19::chr3:172468505..172468582,+	p1@ECT2
4.42e-45	FFCP PHASE1:Hg19::chr3:172468505..172468582,+	p1@ECT2
1.49e-44	FFCP PHASE1:Hg19::chr15:56311466..56311511,+	p@chr15:56311466..56311511, +
1.49e-44	FFCP PHASE2:Hg19::chr15:56311466..56311511,+	p@chr15:56311466..56311511, +
4.62e-44	FFCP PHASE1:Hg19::chr12:20975516..20975562,+	p@chr12:20975516..20975562, +
4.62e-44	FFCP PHASE2:Hg19::chr12:20975516..20975562,+	p@chr12:20975516..20975562, +
6.56e-42	FFCP PHASE2:Hg19::chr15:78857870..78857897,+	p1@CHRNA5
6.56e-42	FFCP PHASE1:Hg19::chr15:78857870..78857897,+	p1@CHRNA5
8.07e-42	FFCP PHASE2:Hg19::chr7:96339167..96339197,-	p2@SHFM1
8.07e-42	FFCP PHASE1:Hg19::chr7:96339167..96339197,-	p2@SHFM1
3.24e-41	FFCP PHASE2:Hg19::chr1:154947148..154947175,+	p1@CKS1B
3.24e-41	FFCP PHASE1:Hg19::chr1:154947148..154947175,+	p1@CKS1B
3.96e-41	FFCP PHASE1:Hg19::chr5:34915805..34915847,+	p1@BRIX1
3.96e-41	FFCP PHASE2:Hg19::chr5:34915805..34915847,+	p1@BRIX1
5.77e-41	FFCP PHASE2:Hg19::chr17:36715685..36715749,-	p3@SRCIN1
5.77e-41	FFCP PHASE1:Hg19::chr17:36715685..36715749,-	p3@SRCIN1
6.49e-41	FFCP PHASE2:Hg19::chr7:105162652..105162709,-	p1@PUS7
6.49e-41	FFCP PHASE1:Hg19::chr7:105162652..105162709,-	p1@PUS7
7.02e-41	FFCP PHASE1:Hg19::chr2:54784868..54784919,+	p@chr2:54784868..54784919, +
7.02e-41	FFCP PHASE2:Hg19::chr2:54784868..54784919,+	p@chr2:54784868..54784919, +
9.49e-41	FFCP PHASE1:Hg19::chr2:238499725..238499747,-	p2@RAB17
9.49e-41	FFCP PHASE2:Hg19::chr2:238499725..238499747,-	p2@RAB17
9.52e-41	FFCP PHASE2:Hg19::chr13:109917833..109917866,+	p@chr13:109917833..109917866, +
9.52e-41	FFCP PHASE1:Hg19::chr13:109917833..109917866,+	p@chr13:109917833..109917866, +
1.46e-40	FFCP PHASE1:Hg19::chr8:124408630..124408647,-	p2@ATAD2
1.46e-40	FFCP PHASE2:Hg19::chr8:124408630..124408647,-	p2@ATAD2
2.64e-40	FFCP PHASE2:Hg19::chr4:57301645..57301675,-	p2@PPAT
2.64e-40	FFCP PHASE1:Hg19::chr4:57301645..57301675,-	p2@PPAT
3.66e-40	FFCP PHASE2:Hg19::chr5:37288836..37288849,-	p@chr5:37288836..37288849, -
3.66e-40	FFCP PHASE1:Hg19::chr5:37288836..37288849,-	p@chr5:37288836..37288849, -
4.73e-40	FFCP PHASE1:Hg19::chr22:22901636..22901715,-	p1@PRAME
4.73e-40	FFCP PHASE2:Hg19::chr22:22901636..22901715,-	p1@PRAME
2.42e-39	FFCP PHASE1:Hg19::chr15:69706740..69706754,+	p2@KIF23
2.42e-39	FFCP PHASE2:Hg19::chr15:69706740..69706754,+	p2@KIF23
3.02e-39	FFCP PHASE1:Hg19::chr7:11012953..11012969,+	p@chr7:11012953..11012969, +
3.02e-39	FFCP PHASE2:Hg19::chr7:11012953..11012969,+	p@chr7:11012953..11012969, +
4.22e-39	FFCP PHASE1:Hg19::chr5:37371163..37371231,-	p1@NUP155
4.22e-39	FFCP PHASE2:Hg19::chr5:37371163..37371231,-	p1@NUP155
1.38e-38	FFCP PHASE2:Hg19::chr7:56119449..56119492,+	p1@CCT6A
1.38e-38	FFCP PHASE1:Hg19::chr7:56119449..56119492,+	p1@CCT6A
2.18e-38	FFCP PHASE1:Hg19::chr17:38444115..38444194,+	p1@CDC6
2.18e-38	FFCP PHASE2:Hg19::chr17:38444115..38444194,+	p1@CDC6
2.62e-38	FFCP PHASE2:Hg19::chr7:1595831..1595858,-	p1@TMEM184A
2.62e-38	FFCP PHASE1:Hg19::chr7:1595831..1595858,-	p1@TMEM184A
3.07e-38	FFCP PHASE2:Hg19::chr17:62770351..62770363,-	p@chr17:62770351..62770363, -
3.07e-38	FFCP PHASE1:Hg19::chr17:62770351..62770363,-	p@chr17:62770351..62770363, -
3.5e-38	FFCP PHASE2:Hg19::chr2:70529150..70529179,-	p1@FAM136A
3.5e-38	FFCP PHASE1:Hg19::chr2:70529150..70529179,-	p1@FAM136A
4.66e-38	FFCP PHASE1:Hg19::chr12:50419141..50419170,-	p2@RACGAP1
4.66e-38	FFCP PHASE2:Hg19::chr12:50419141..50419170,-	p2@RACGAP1
4.66e-38	FFCP PHASE1:Hg19::chr12:54332608..54332636,+	p1@HOXC13
4.66e-38	FFCP PHASE2:Hg19::chr12:54332608..54332636,+	p1@HOXC13
5.57e-38	FFCP PHASE1:Hg19::chr12:118454500..118454585,+	p1@RFC5
5.57e-38	FFCP PHASE2:Hg19::chr12:118454500..118454585,+	p1@RFC5
6.1e-38	FFCP PHASE2:Hg19::chrX:27417088..27417131,-	p1@ENST00000422048, p1@uc004dbt.2
6.1e-38	FFCP PHASE1:Hg19::chrX:27417088..27417131,-	p1@ENST00000422048, p1@uc004dbt.2
9.54e-38	FFCP PHASE1:Hg19::chr11:66139128..66139152,-	p3@SLC29A2
9.54e-38	FFCP PHASE2:Hg19::chr11:66139128..66139152,-	p3@SLC29A2
1.24e-37	FFCP PHASE1:Hg19::chr2:198364552..198364576,-	p1@HSPD1
1.24e-37	FFCP PHASE2:Hg19::chr2:198364552..198364576,-	p1@HSPD1
1.55e-37	FFCP PHASE1:Hg19::chr2:174562443..174562467,+	p@chr2:174562443..174562467, +
1.55e-37	FFCP PHASE2:Hg19::chr2:174562443..174562467,+	p@chr2:174562443..174562467, +
2.03e-37	FFCP PHASE1:Hg19::chr2:29117521..29117569,+	p1@WDR43
2.03e-37	FFCP PHASE2:Hg19::chr2:29117521..29117569,+	p1@WDR43
2.33e-37	FFCP PHASE2:Hg19::chr17:43503012..43503035,-	p4@ARHGAP27
2.33e-37	FFCP PHASE1:Hg19::chr17:43503012..43503035,-	p4@ARHGAP27
2.57e-37	FFCP PHASE1:Hg19::chr16:2955389..2955405,-	p@chr16:2955389..2955405, -
2.57e-37	FFCP PHASE2:Hg19::chr16:2955389..2955405,-	p@chr16:2955389..2955405, -
3.09e-37	FFCP PHASE1:Hg19::chr1:235268802..235268805,-	p@chr1:235268802..235268805, -
3.09e-37	FFCP PHASE2:Hg19::chr1:235268802..235268805,-	p@chr1:235268802..235268805, -
4.54e-37	FFCP PHASE1:Hg19::chr5:10250349..10250362,+	p2@CCT5
4.54e-37	FFCP PHASE2:Hg19::chr5:10250349..10250362,+	p2@CCT5
5.03e-37	FFCP PHASE2:Hg19::chr3:194040598..194040638,-	p@chr3:194040598..194040638, -
5.03e-37	FFCP PHASE1:Hg19::chr3:194040598..194040638,-	p@chr3:194040598..194040638, -
8.27e-37	FFCP PHASE2:Hg19::chr7:1595804..1595828,-	p3@TMEM184A
8.27e-37	FFCP PHASE1:Hg19::chr7:1595804..1595828,-	p3@TMEM184A
1.08e-36	FFCP PHASE2:Hg19::chr10:96363899..96363904,+	p@chr10:96363899..96363904, +
1.08e-36	FFCP PHASE1:Hg19::chr10:96363899..96363904,+	p@chr10:96363899..96363904, +
1.73e-36	FFCP PHASE2:Hg19::chr18:47376197..47376227,-	p2@MYO5B
1.73e-36	FFCP PHASE1:Hg19::chr18:47376197..47376227,-	p2@MYO5B
1.81e-36	FFCP PHASE1:Hg19::chr13:114103443..114103479,-	p2@ADPRHL1
1.81e-36	FFCP PHASE2:Hg19::chr13:114103443..114103479,-	p2@ADPRHL1

Showing 1 to 100 of 100 entries